Clinical Trial Goal
To find out:
- The highest dose of STX-0712 that's safe to give
- If STX-0712 is safe and works well to treat AML or CMML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML or CMML that has relapsed or is refractory
- Do not have acute any of the following:
- Acute promyelocytic leukemia
- Myelodysplastic syndrome (MDS)
- Myeloproliferative neoplasm (MPN)
- Are not able to have an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Have not had a BMT in the last 6 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
STX-0712 is a cytotoxicity targeting chimera (CyTAC) that targets GPCR CCR2 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- STX-0712 – Given as an intravenous (IV) infusion 1 time
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved STX-0712.
Locations
Sponsors
lead: Solu Therapeutics, Inc
